Q-linea AB (publ) (STO:QLINEA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 346.76M +13.8% |
| Revenue (ttm) | 11.81M +62.0% |
| Net Income | -170.83M |
| EPS | -15.77 |
| Shares Out | 18.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,706 |
| Open | 18.10 |
| Previous Close | 18.65 |
| Day's Range | 18.10 - 18.70 |
| 52-Week Range | 14.55 - 79.00 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | 50.00 (0.0%) |
| Earnings Date | Jul 10, 2026 |
About Q-linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood cult... [Read more]
Financial Performance
In 2025, Q-linea AB's revenue was 15.29 million, an increase of 269.29% compared to the previous year's 4.14 million. Losses were -182.49 million, -15.86% less than in 2024.
Financial StatementsNews
Q-linea AB Earnings Call Transcript: Q1 2026
Record Q1 for instrument placements and consumables demand, driven by FDA V2 menu clearance in the U.S. and steady European growth. OpEx reduced 47% year-over-year, with a strong pipeline and new product launches expected to accelerate growth.
Q-linea AB Quarterly report: Q1 2026
Q-linea AB has published its Q1 2026 quarterly earnings report on April 30, 2026.
Q-linea AB Slides: Q1 2026
Q-linea AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Q-linea AB Earnings Call Transcript: Q4 2025
Revenue grew over 400% year-over-year in 2025, driven by instrument placements and consumables. U.S. growth is expected to accelerate after FDA clearance in 2026, with breakeven targeted for 2027. OpEx reductions and strong liquidity position support continued expansion.
Q-linea AB Quarterly report: Q4 2025
Q-linea AB has published its Q4 2025 quarterly earnings report on February 4, 2026.
Q-linea AB Slides: Q4 2025
Q-linea AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 4, 2026.
Q-linea AB Annual report: Q4 2025
Q-linea AB has published its Q4 2025 annual report on February 4, 2026.
Q-linea AB Earnings Call Transcript: Q3 2025
Recurring income grew 370% year-over-year, driven by increased instrument activations and consumables demand, with a robust pipeline in over 15 countries. Cost reductions and a major rights issue secure liquidity, while FDA clearance for the V2 menu remains a key near-term catalyst.
Q-linea AB Quarterly report: Q3 2025
Q-linea AB has published its Q3 2025 quarterly earnings report on October 20, 2025.
Q-linea AB Slides: Q3 2025
Q-linea AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 20, 2025.
Q-linea AB Earnings Call Transcript: Q2 2025
Q2 saw five new instrument placements, strong pipeline growth, and robust cost control. Financials improved year-over-year, with a completed capital raise and clear path to break-even by 2027. Italy leads adoption, while the U.S. and other regions are progressing through early stages.
Q-linea AB Quarterly report: Q2 2025
Q-linea AB has published its Q2 2025 quarterly earnings report on July 10, 2025.
Q-linea AB Slides: Q2 2025
Q-linea AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 10, 2025.